




FIGURE 1B




FIGURE 1A




FIGURE 2




FIGURE 3




FIGURE 4B




FIGURE 4A




FIGURE 4C




FIGURE 5




FIGURE 6

8/33





FIGURE 7A

9/33

**FIGURE 7B**

10/33




FIGURE 7C





FIGURE 8

12/33

**FIGURE 8 Continued**

13/33




FIGURE 8 Continued









FIGURE 9



16/33

**FIGURE 11**








FIGURE 14

20/33

CAR T cell manufacturing plan**Selection of CD4+ and CD8+ Cells from Autologous Patient Apheresis Product****Apheresis collection**

Selection of CD4+ and CD8+ T cells with Miltenyi beads



Cryopreservation of CD4+/CD8+ cellular product in 10% HSA in Plasmalyte mixed with CS10 at 1:1 (volume: volume) ratio, and determine the % of CD3+ in the cryopreserved cellular product

**ADCLEC.syn1 CAR T cell Production****[Day 0] Activation**

Thaw CD8+/CD4+ T cells at 37 °C

Wash cells with 3 volumes of 1% HSA in Plasmalyte by centrifugation at 300xg for 10 min



Count the cell numbers of washed CD8+/CD4+ T cells



Based on %CD3+ cells, resuspend 100E6 to 300E6 CD3+ cells in complete X-Vivo15 media (X-Vivo15 + 5% human AB serum + 1x Glutamax + 20mM HEPES + 1mM sodium pyruvate + 1x MEM vitamin solution + 1.6 mg/mL N-Acetylcysteine) + 45 mg/mL Gentamicin + 20 IU/mL IL7 + 100 IU/mL IL15

FIGURE 15

SUBSTITUTE SHEET (RULE 26)

21/33



Activate T cells with Dynabeads® ClinEx Vivo CD3/CD28 using a bead to T cell ratio of 1:1 for approximately 48hr in a 37 °C incubator with 5% CO₂

**[Day 2] Transduction**

Transduce the activated T cells with ADCLEC.syn1 vector stocks in PL72/PL240 bag with overwrap pouch/seal. Spin at 1200 rpm for 60 min at RT at 0.5E6 cells/mL

**[Day 3]**

Transfer the transduced cells to the G-Rex bioreactor and grow the cells in complete X-Vivo15 media w/o gentamicin

**[Day 7 and Day 10]**

Spike IL7 and IL15 into the medium to maintain 20 IU/mL IL7 + 100 IU/mL IL15

**[Day ≤ 14]**

When the target number of cells is reached, wash the cells with 1%HSA in 1x Plasmalyte A using a closed system cell washer & de bead using a ClinExVivo magnet

**FIGURE 15 Continued**

22/33

Cryopreservation and Storage of the Final Product

Formulate the final product in Cryostor CS10 cryopreservation buffer (50% CS10 + 5% HSA in Plasmalyte)



Store the final product in approximately 1 mL to 130 mL in CellSeal vial 2 mL, Cell Seal vial 5 mL, CryoStor 50, CryoStor 250 bags or equivalent in vapor-phase liquid nitrogen

FIGURE 15 Continued

23/33




FIGURE 16




FIGURE 17A





FIGURE 17B



IF--THEN--GATE

³⁹Requires antigen A to induce CAR for antigen B³⁹

Increases tumor selectivity

syn-Notch receptor + 2nd-gen. CAR




FIGURE 18A Continued

27/33

IF-BETTER-GATE
(here via ADCLEC.syn platform in AML)

*"Requires (1) high antigen A alone or
(2) low antigen A and antigen B"*

Prevents antigen-low relapse via
gated sensitivity enhancement

2nd-gen. CAR (affinity/CD3 ζ -fine-tuned) + CCR




FIGURE 18B





FIGURE 19A




FIGURE 19B

30/33




FIGURE 20

31/33




FIGURE 20 Continued

SUBSTITUTE SHEET (RULE 26)

32/33




FIGURE 20 Continued

SUBSTITUTE SHEET (RULE 26)





FIGURE 21